Breaking News
Investing Pro 0

Roche shares fall after Alzheimer's drug trials fail to meet primary goals

Stock Markets Nov 14, 2022 05:39AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
ROG
+2.61%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
LLY
-3.46%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4523
-0.83%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Scott Kanowsky 

Investing.com -- Roche Holding AG Participation (SIX:ROG) says two long-awaited late-stage studies showed that its Alzheimer's disease treatment failed to stem a slide in the cognitive abilities of people with an early form of the illness.

In a statement on Monday, the Swiss pharmaceutical firm said results from the Phase III trials of the drug - known as gantenerumab - failed to meet their "primary endpoint" of slowing the clinical decline in patients with mild dementia due to Alzheimer's.

Shares in Roche fell in early trading.

"So many of our families have been directly affected by Alzheimer's, so this news is very disappointing to deliver," said Roche chief medical officer Levi Garraway.

The failure of gantenerumab deals a blow to the so-called amyloid hypothesis or a theory that the clearing of toxic cells clumping together in the brain will help ease cognitive loss in people suffering from Alzheimer's. Roche, as well as rival Eli Lilly and Company (NYSE:LLY) and Japan's Eisai (TYO:4523), have been aiming to create a medicine that harnesses this theory, with a successful treatment set to potentially generate billions of dollars in sales.

Alzheimer's disease - a neurological disorder that causes the brain to shrink in size and cells to die - has impacted an estimated 55 million people worldwide as recently as 2020, according to the advocacy group Alzheimer's Disease International. There is currently no known cure.

In a note to clients, analysts at Stifel called Roche's announcement a "major negative" for the firm.

"This is the end of this development, that will have to be removed from the sales models. It also removes a significant growth driver for the company over the next few years," the analysts said.

Roche's 2023 financial guidance will now be "highly exposed" to a potential hit worth CHF 3-4 billion (CHF 1 = $1.0552), resulting in a no-growth year for the group, they added.

Roche shares fall after Alzheimer's drug trials fail to meet primary goals
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (3)
Roberta saunders
Roberta saunders Nov 14, 2022 7:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
If you read “ The physiology of boredom depression and senile dementia” by M.N.Saunders in kundoc.com you will understand why the trial failed.
Prosper Karimupfumbi
Prosper Karimupfumbi Nov 14, 2022 7:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
JJ JJ u r too funnie
JJ JJ
JJ JJ Nov 14, 2022 6:30AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Did they test the medication on John Biden??
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email